{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:32Z","timestamp":1787026592991,"version":"build-2736575974"},"reference-count":141,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    More than 200 cases of lipoprotein glomerulopathy (LPG) have been reported since it was first discovered 30 years ago. Although relatively rare, LPG is clinically an important cause of nephrotic syndrome and end-stage renal disease. Mutations in the\n                    <jats:italic>APOE<\/jats:italic>\n                    gene are the leading cause of LPG.\n                    <jats:italic>APOE<\/jats:italic>\n                    mutations are an important determinant of lipid profiles and cardiovascular health in the population and can precipitate dysbetalipoproteinemia and glomerulopathy. Apolipoprotein E-related glomerular disorders include\n                    <jats:italic>APOE<\/jats:italic>\n                    2 homozygote glomerulopathy and LPG with heterozygous\n                    <jats:italic>APOE<\/jats:italic>\n                    mutations. In recent years, there has been a rapid increase in the number of LPG case reports and some progress in research into the mechanism and animal models of LPG. We consequently need to update recent epidemiological studies and the molecular mechanisms of LPG. This endeavor may help us not only to diagnose and treat LPG in a more personized manner but also to better understand the potential relationship between lipids and the kidney.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2022.905007","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T02:14:49Z","timestamp":1651803289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy"],"prefix":"10.3389","volume":"9","author":[{"given":"Meng-shi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"B1","first-page":"1667","volume":"47","author":"Watanabe","year":"1989","journal-title":"Nihon Rinsho"},{"key":"B2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2005.10.017","article-title":"Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases","volume":"47","author":"Saito","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s10157-013-0887-4","article-title":"Topics in lipoprotein glomerulopathy: an overview","volume":"18","author":"Saito","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0272-6386(89)80134-9","article-title":"Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia","volume":"13","author":"Saito","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"B5","first-page":"1590","volume":"71","author":"Eto","year":"2013","journal-title":"Nihon Rinsho"},{"key":"B6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0272-6386(12)80649-4","article-title":"Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy","volume":"18","author":"Oikawa","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/ki.2013.335","article-title":"Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation","volume":"85","author":"Hu","year":"2014","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000111828","article-title":"Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy","volume":"28","author":"Luo","year":"2008","journal-title":"Am J Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/MOL.0b013e328345ebb0","article-title":"Lipoprotein glomerulopathy","volume":"22","author":"Tsimihodimos","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2054358119859576","DOI":"10.1177\/2054358119859576","article-title":"Lipoprotein glomerulopathy in a hispanic female: a case report and literature review","volume":"6","author":"Majeed","year":"2019","journal-title":"Can J Kidney Health Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/ki.2013.404","article-title":"Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis","volume":"85","author":"Saito","year":"2014","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/jhg.2013.8","article-title":"A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy","volume":"58","author":"Toyota","year":"2013","journal-title":"J Hum Genet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"684814","DOI":"10.3389\/fped.2021.684814","article-title":"Case report: a pediatric case of lipoprotein glomerulopathy in china and literature review","volume":"9","author":"Song","year":"2021","journal-title":"Front Pediatr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/CM9.0000000000000050","article-title":"A novel apolipoprotein E mutation (p.Arg150Cys) in a Chinese patient with lipoprotein glomerulopathy","volume":"132","author":"Ku","year":"2019","journal-title":"Chin Med J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5935\/0101-2800.20140015","article-title":"Lipoprotein glomerulopathy: a case report of a rare disease in a Brazilian child","volume":"36","author":"P\u00eagas","year":"2014","journal-title":"J Bras Nefrol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.ajkd.2005.12.031","article-title":"Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding","volume":"47","author":"Sam","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.17116\/patol201678652-57","volume":"78","author":"Sipovskii","year":"2016","journal-title":"Arkh Patol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5301\/JN.2011.7772","article-title":"Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town","volume":"24","author":"Pasquariello","year":"2011","journal-title":"J Nephrol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/ndt\/10.4.546","article-title":"Lipoprotein glomerulopathy: first case in a white European","volume":"10","author":"Meyrier","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"B20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s11255-021-02930-7","article-title":"A case of lipoprotein glomerulopathy in a Greek Caucasian male","volume":"54","author":"Marinaki","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1281","DOI":"10.1002\/mgg3.1281","article-title":"Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations","volume":"8","author":"Yang","year":"2020","journal-title":"Mol Genet Genomic Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13000-019-0820-6","article-title":"A novel apolipoprotein E mutation caused by a five amino acid deletion in a Chinese family with lipoprotein glomerulopathy: a case report","volume":"14","author":"Xie","year":"2019","journal-title":"Diagn Pathol"},{"key":"B23","first-page":"110","article-title":"Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy","volume":"21","author":"Zhang","year":"2008","journal-title":"J Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1638\/2015-0245.1","article-title":"Spontaneous lipoprotein glomerulopathy-like nephropathy in a squirrel (Sciurus vulgaris)","volume":"47","author":"Kobayashi","year":"2016","journal-title":"J zoo Wildl Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.arr.2017.06.002","article-title":"Evolution of human apolipoprotein E (APOE) isoforms: gene structure, protein function and interaction with dietary factors","volume":"37","author":"Huebbe","year":"2017","journal-title":"Ageing Res Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0002-9440(10)65305-9","article-title":"Specific regional transcription of apolipoprotein E in human brain neurons","volume":"154","author":"Xu","year":"1999","journal-title":"Am J Pathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000487919","article-title":"Membranous nephropathy-like apolipoprotein E deposition disease with apolipoprotein E toyonaka (Ser197Cys) and a homozygous apolipoprotein E2\/2","volume":"8","author":"Fukunaga","year":"2018","journal-title":"Case Rep Nephrol Dial"},{"key":"B28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s13730-018-0331-4","article-title":"Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys)","volume":"7","author":"Sasaki","year":"2018","journal-title":"CEN Case Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1021\/bi9017208","article-title":"Decoding of lipoprotein-receptor interactions: properties of ligand binding modules governing interactions with apolipoprotein E","volume":"49","author":"Guttman","year":"2010","journal-title":"Biochemistry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0006-291X(86)80489-2","article-title":"Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains","volume":"134","author":"Cardin","year":"1986","journal-title":"Biochem Biophys Res Commun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.csbj.2017.05.003","article-title":"Apolipoprotein E - a multifunctional protein with implications in various pathologies as a result of its structural features","volume":"15","author":"Tudorache","year":"2017","journal-title":"Comput Struct Biotechnol J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.nbd.2014.08.025","article-title":"Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases","volume":"72","author":"Huang","year":"2014","journal-title":"Neurobiol Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tibs.2006.06.008","article-title":"Apolipoprotein E structure: insights into function","volume":"31","author":"Hatters","year":"2006","journal-title":"Trends Biochem Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/iub.1314","article-title":"Apolipoprotein E isoforms and lipoprotein metabolism","volume":"66","author":"Phillips","year":"2014","journal-title":"IUBMB Life"},{"key":"B35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0272-6386(12)70173-7","article-title":"Lipoprotein metabolism","volume":"22","author":"Illingworth","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0022-2275(20)34443-6","article-title":"Plasma lipoproteins: apolipoprotein structure and function","volume":"25","author":"Mahley","year":"1984","journal-title":"J Lipid Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.atherosclerosis.2018.06.881","article-title":"Endocytosis of lipoproteins","volume":"275","author":"Zanoni","year":"2018","journal-title":"Atherosclerosis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.2337\/dc16-0843","article-title":"APOE genotypes associate with cognitive performance but not cerebral structure: diabetes heart study mind","volume":"39","author":"Palmer Allred","year":"2016","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/alz.12153","article-title":"The APOE \u03b54 exerts differential effects on familial and other subtypes of Alzheimer's disease","volume":"16","author":"Jia","year":"2020","journal-title":"Alzheimers Dement"},{"key":"B40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-981-13-1117-8_5","article-title":"ApoE and neurodegenerative diseases in aging","volume":"1086","author":"Yin","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s11064-018-2629-1","article-title":"Understanding the role of ApoE fragments in Alzheimer's disease","volume":"44","author":"Mu\u00f1oz","year":"2019","journal-title":"Neurochem Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.pathol.2018.11.002","article-title":"Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease","volume":"51","author":"Marais","year":"2019","journal-title":"Pathology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1681\/ASN.V85820","article-title":"Apolipoprotein E Sendai (arginine 145\u2013>proline): a new variant associated with lipoprotein glomerulopathy","volume":"8","author":"Oikawa","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1681\/ASN.V85840","article-title":"Lipoprotein glomerulopathy: a new role for apolipoprotein E?","volume":"8","author":"Karet","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"31269","DOI":"10.1074\/jbc.M005906200","article-title":"Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice","volume":"275","author":"Ishigaki","year":"2000","journal-title":"J Biol Chem"},{"key":"B46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12967-021-02765-x","article-title":"Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice","volume":"19","author":"Wu","year":"2021","journal-title":"J Transl Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e28718","DOI":"10.1097\/MD.0000000000028718","article-title":"Lipoprotein glomerulopathy resulting from compound heterogeneous mutations of APOE gene: a case report","volume":"101","author":"Li","year":"2022","journal-title":"Medicine"},{"key":"B48","first-page":"57","article-title":"A rare cause of nephrotic syndrome: lipoprotein glomerulopathy","volume":"15","author":"Cheung","year":"2009","journal-title":"Hong Kong Med J"},{"key":"B49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000478902","article-title":"A case of lipoprotein glomerulopathy with apoE Chicago and apoE (Glu3Lys) treated with fenofibrate","volume":"7","author":"Kodera","year":"2017","journal-title":"Case Rep Nephrol Dial"},{"key":"B50","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1194\/jlr.M030965","article-title":"Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy","volume":"54","author":"Georgiadou","year":"2013","journal-title":"J Lipid Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1006\/jmbi.1998.2217","article-title":"Proline-induced disruption of a transmembrane alpha-helix in its natural environment","volume":"284","author":"Nilsson","year":"1998","journal-title":"J Mol Biol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"E6822","DOI":"10.1073\/pnas.1707974114","article-title":"Exploiting conformational plasticity in the AAA+ protein VCP\/p97 to modify function","volume":"114","author":"Sch\u00fctz","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1194\/jlr.M088732","article-title":"Thermodynamic destabilization and aggregation propensity as the mechanism behind the association of apoE3 mutants and lipoprotein glomerulopathy","volume":"59","author":"Katsarou","year":"2018","journal-title":"J Lipid Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jmb.2006.06.080","article-title":"Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils","volume":"361","author":"Hatters","year":"2006","journal-title":"J Mol Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.atherosclerosis.2018.02.015","article-title":"Hyperlipidemia induces typical atherosclerosis development in Ldlr and Apoe deficient rats","volume":"271","author":"Zhao","year":"2018","journal-title":"Atherosclerosis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"165972","DOI":"10.1016\/j.bbadis.2020.165972","article-title":"Age-related and atherosclerosis-related erythropathy in ApoE\/LDLR(-\/-) mice","volume":"1866","author":"Dybas","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1681\/ASN.V123524","article-title":"Diminished LDL receptor and high heparin binding of apolipoprotein E2 sendai associated with lipoprotein glomerulopathy","volume":"12","author":"Hoffmann","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1046\/j.1523-1755.1999.00572.x","article-title":"A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy","volume":"56","author":"Matsunaga","year":"1999","journal-title":"Kidney Int"},{"key":"B59","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1590\/2175-8239-jbn-2018-0148","article-title":"Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: a review","volume":"41","author":"Cambruzzi","year":"2019","journal-title":"J Bras Nefrol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1515\/hsz-2019-0283","article-title":"Space of disse: a stem cell niche in the liver","volume":"401","author":"H\u00e4ussinger","year":"2019","journal-title":"Biol Chem"},{"key":"B61","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jconrel.2020.03.006","article-title":"Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E\/low density lipoprotein receptor and the N-acetyl-d-galactosamine\/asialoglycoprotein receptor pathway","volume":"322","author":"Sato","year":"2020","journal-title":"J Control Release"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1248\/bpb.b15-00716","article-title":"Metabolism and modification of apolipoprotein B-containing lipoproteins involved in dyslipidemia and atherosclerosis","volume":"39","author":"Morita","year":"2016","journal-title":"Biol Pharm Bull"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-2275(20)33334-4","article-title":"Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E","volume":"40","author":"Mahley","year":"1999","journal-title":"J Lipid Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/bs.ircmb.2016.02.009","article-title":"Heparan sulfate: biosynthesis, structure, and function","volume":"325","author":"Li","year":"2016","journal-title":"Int Rev Cell Mol Biol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/meta.2002.29990","article-title":"Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg25[rarr ]Cys) from a patient with lipoprotein glomerulopathy","volume":"51","author":"Murano","year":"2002","journal-title":"Metabolism"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1093\/ndt\/12.11.2442","article-title":"Recurrence of lipoprotein glomerulopathy after renal transplantation","volume":"12","author":"Andrews","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1681\/ASN.V1071590","article-title":"Apolipoprotein E2\/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney","volume":"10","author":"Miyata","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1097\/01.ASN.0000015615.14428.67","article-title":"Chronic graft-versus-host autoimmune disease in Fc receptor gamma chain-deficient mice results in lipoprotein glomerulopathy","volume":"13","author":"Kanamaru","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0005-2760(98)00127-1","article-title":"Receptors for oxidized low density lipoprotein","volume":"1436","author":"Steinbrecher","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"B71","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0092-8674(94)90115-5","article-title":"FcR gamma chain deletion results in pleiotrophic effector cell defects","volume":"76","author":"Takai","year":"1994","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1093\/ndt\/gfs329","article-title":"Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities","volume":"27","author":"Ito","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B73","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1006\/clin.1995.1069","article-title":"Activation of human monocyte-derived macrophages by immune complexes containing low-density lipoprotein","volume":"75","author":"Virella","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"22446","DOI":"10.1016\/S0021-9258(18)41692-4","article-title":"A macrophage Fc receptor for IgG is also a receptor for oxidized low density lipoprotein","volume":"267","author":"Stanton","year":"1992","journal-title":"J Biol Chem"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1084\/jem.168.3.1041","article-title":"Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation","volume":"168","author":"Griffith","year":"1988","journal-title":"J Exp Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1194\/jlr.M200108-JLR200","article-title":"Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice","volume":"43","author":"Fazio","year":"2002","journal-title":"J Lipid Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"C586","DOI":"10.1152\/ajpcell.00210.2004","article-title":"ApoE-mediated cholesterol efflux from macrophages: separation of autocrine and paracrine effects","volume":"288","author":"Dove","year":"2005","journal-title":"Am J Physiol Cell Physiol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1194\/jlr.M049874","article-title":"Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice","volume":"55","author":"Tavori","year":"2014","journal-title":"J Lipid Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/prot.20080","article-title":"Apolipoprotein E-low density lipoprotein receptor binding: study of protein-protein interaction in rationally selected docked complexes","volume":"55","author":"Pr\u00e9vost","year":"2004","journal-title":"Proteins"},{"key":"B80","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S2213-8587(14)70065-8","article-title":"Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease","volume":"2","author":"de Vries","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3390\/nu11040722","article-title":"Lipid accumulation and chronic kidney disease","volume":"11","author":"Gai","year":"2019","journal-title":"Nutrients"},{"key":"B82","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1096\/fasebj.11.11.9285483","article-title":"The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis","volume":"11","author":"Leonarduzzi","year":"1997","journal-title":"FASEB J"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1097-4644(19990101)72:1<1::AID-JCB1>3.0.CO;2-Y","article-title":"Carbonyl compounds cross-link cellular proteins and activate protein-tyrosine kinase p60c-Src","volume":"72","author":"Akhand","year":"1999","journal-title":"J Cell Biochem"},{"key":"B84","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1046\/j.1523-1755.1999.00302.x","article-title":"Alterations in nonenzymatic biochemistry in uremia: origin and significance of carbonyl stress in long-term uremic complications","volume":"55","author":"Miyata","year":"1999","journal-title":"Kidney Int"},{"key":"B85","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1021\/bi0472696","article-title":"The receptor binding domain of apolipoprotein E is responsible for its antioxidant activity","volume":"44","author":"Pham","year":"2005","journal-title":"Biochemistry"},{"key":"B86","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000187897","article-title":"A case of lipoprotein glomerulopathy successfully treated with probucol","volume":"67","author":"Amenomori","year":"1994","journal-title":"Nephron"},{"key":"B87","first-page":"568","article-title":"A complete genomic analysis of the apolipoprotein E gene in Chinese patients with lipoprotein glomerulopathy","volume":"20","author":"Chen","year":"2007","journal-title":"J Nephrol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"734824","DOI":"10.3389\/fcvm.2021.734824","article-title":"Lipoprotein glomerulopathy-like lesions in atherosclerotic mice defected with HDL receptor SR-B1","volume":"8","author":"Liao","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000355810","article-title":"Apolipoprotein e mutation and double filtration plasmapheresis therapy on a new Chinese patient with lipoprotein glomerulopathy","volume":"39","author":"Li","year":"2014","journal-title":"Kidney Blood Press Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1752-1947-3-9311","article-title":"Lipoprotein glomerulopathy treated with LDL-apheresis (heparin-induced extracorporeal lipoprotein precipitation system): a case report","volume":"3","author":"Russi","year":"2009","journal-title":"J Med Case Rep"},{"key":"B91","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000441715","article-title":"Macrophage infiltration into the glomeruli in lipoprotein glomerulopathy","volume":"5","author":"Takasaki","year":"2015","journal-title":"Case Rep Nephrol Dial"},{"key":"B92","doi-asserted-by":"publisher","first-page":"536","DOI":"10.5551\/jat.8102","article-title":"A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy","volume":"18","author":"Tokura","year":"2011","journal-title":"J Atheroscler Thromb"},{"key":"B93","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0021-9150(03)00194-1","article-title":"Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy","volume":"169","author":"Arai","year":"2003","journal-title":"Atherosclerosis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"733","DOI":"10.5551\/jat.41996","article-title":"The novel apolipoprotein e mutation ApoE chengdu (c.518T>C, p.L173P) in a Chinese patient with lipoprotein glomerulopathy","volume":"25","author":"Wu","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"B95","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1471-2369-14-53","article-title":"A case of lipoprotein glomerulopathy with thrombotic microangiopathy due to malignant hypertension","volume":"14","author":"Wu","year":"2013","journal-title":"BMC Nephrol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3760\/cma.j.issn.0366-6999.2004.10.114","article-title":"Lipoprotein glomerulopathy: clinical features and pathological characteristics in Chinese","volume":"117","author":"Chen","year":"2004","journal-title":"Chin Med J"},{"key":"B97","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/ndt\/gfn555","article-title":"Successful treatment of patients with lipoprotein glomerulopathy by protein A immunoadsorption: a pilot study","volume":"24","author":"Xin","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B98","doi-asserted-by":"publisher","first-page":"555","DOI":"10.5555\/cmj.0366-6999.118.07.p555.01","article-title":"Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy","volume":"118","author":"Zhang","year":"2005","journal-title":"Chin Med J"},{"key":"B99","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s13730-018-0309-2","article-title":"A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I","volume":"7","author":"Takasaki","year":"2018","journal-title":"CEN Case Rep"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.3760\/cma.j.issn.0376-2491.2018.36.007","volume":"98","author":"Zou","year":"2018","journal-title":"Chin Med J"},{"key":"B101","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.pcad.2016.07.007","article-title":"Type III hyperlipoproteinemia: still worth considering?","volume":"59","author":"Blum","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.jacl.2018.09.006","article-title":"The spectrum of type III hyperlipoproteinemia","volume":"12","author":"Sniderman","year":"2018","journal-title":"J Clin Lipidol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-Rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/10408363.2020.1745142","article-title":"The clinical and laboratory investigation of dysbetalipoproteinemia","volume":"57","author":"Boot","year":"2020","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B105","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/BF00858822","article-title":"Long-term follow-up of a paediatric case of lipoprotein glomerulopathy","volume":"4","author":"Koitabashi","year":"1990","journal-title":"Pediatr Nephrol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13000-021-01119-x","article-title":"Lipoprotein glomerulopathy associated with the Osaka\/Kurashiki APOE variant: two cases identified in Latin America","volume":"16","author":"da Silveira-Neto","year":"2021","journal-title":"Diagn Pathol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"679048","DOI":"10.3389\/fmed.2021.679048","article-title":"Case report: lipoprotein glomerulopathy complicated by atypical hemolytic uremic syndrome","volume":"8","author":"Kollbrunner","year":"2021","journal-title":"Front Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1016\/S0272-6386(03)00798-4","article-title":"Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3\/3","volume":"42","author":"Chang","year":"2003","journal-title":"Am J kidney Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1046\/j.1523-1755.1999.00677.x","article-title":"A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy","volume":"56","author":"Ando","year":"1999","journal-title":"Kidney Int"},{"key":"B110","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.carpath.2019.04.006","article-title":"Intravascular cardiac lipoproteinosis: extrarenal manifestation of lipoprotein glomerulopathy","volume":"42","author":"Morris","year":"2019","journal-title":"Cardiovasc Pathol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jacl.2018.12.004","article-title":"A young Chinese man with nephrotic syndrome due to lipoprotein glomerulopathy","volume":"13","author":"Lui","year":"2019","journal-title":"J Clin Lipidol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1093\/ndt\/gfq389","article-title":"A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy","volume":"25","author":"Bomback","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"B113","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0272-6386(12)81066-3","article-title":"Lipoprotein glomerulopathy: first report in a Chinese male","volume":"24","author":"Zhang","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"B114","doi-asserted-by":"publisher","first-page":"279","DOI":"10.5858\/134.2.279","article-title":"A rare case of lipoprotein glomerulopathy in a white man: an emerging entity in Asia, rare in the white population","volume":"134","author":"Boumendjel","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/ndt\/gfm675","article-title":"A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy","volume":"23","author":"Kinomura","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B116","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s13730-016-0214-5","article-title":"Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation","volume":"5","author":"Usui","year":"2016","journal-title":"CEN Case Rep"},{"key":"B117","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1442-200x.2001.01344.x","article-title":"A newborn infant with lipoprotein glomerulopathy associated with congenital nephrotic syndrome","volume":"43","author":"Shimizu","year":"2001","journal-title":"Pediatr Int"},{"key":"B118","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000045513","article-title":"Association of a novel 3-amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy","volume":"83","author":"Konishi","year":"1999","journal-title":"Nephron"},{"key":"B119","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000276578","article-title":"Common apolipoprotein e gene mutations contribute to lipoprotein glomerulopathy in China","volume":"114","author":"Han","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"B120","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/MOL.0000000000000199","article-title":"Did we abandon probucol too soon?","volume":"26","author":"Yamashita","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1053\/ajkd.2003.50016","article-title":"Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy","volume":"41","author":"Ieiri","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B122","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s10157-007-0469-4","article-title":"Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)\/3 heterozygosity","volume":"11","author":"Karube","year":"2007","journal-title":"Clin Exp Nephrol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0002-9343(02)01567-X","article-title":"Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial","volume":"114","author":"Owada","year":"2003","journal-title":"Am J Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/0149-2918(95)80006-9","article-title":"Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a)","volume":"17","author":"Yamauchi","year":"1995","journal-title":"Clin Ther"},{"key":"B125","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10157-010-0333-9","article-title":"Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol","volume":"14","author":"Hamatani","year":"2010","journal-title":"Clin Exp Nephrol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"key":"B127","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5414\/CN106876","article-title":"A rare cause of childhood-onset nephrotic syndrome: lipoprotein glomerulopathy","volume":"78","author":"Liao","year":"2012","journal-title":"Clin Nephrol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10157-009-0207-1","article-title":"Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy","volume":"13","author":"Matsunaga","year":"2009","journal-title":"Clin Exp Nephrol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3390\/cells10071815","article-title":"Sodium-Glucose cotransporter-2 inhibitors in patients with hereditary podocytopathies, alport syndrome, and FSGS: a case series to better plan a large-scale study","volume":"10","author":"Boeckhaus","year":"2021","journal-title":"Cells"},{"key":"B130","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1046\/j.1526-0968.2001.00371.x","article-title":"Heparin-Induced extracorporeal low-density lipoprotein precipitation futura, a new modification of HELP apheresis: technique and first clinical results","volume":"5","author":"Susca","year":"2001","journal-title":"Ther Apher"},{"key":"B131","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.pathol.2018.10.016","article-title":"Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)","volume":"51","author":"Waldmann","year":"2019","journal-title":"Pathology"},{"key":"B132","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1681\/ASN.V1092014","article-title":"Effect of protein A immunoadsorption in nephrotic syndrome of various etiologies","volume":"10","author":"Esnault","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2217\/pgs-2019-0092","article-title":"Activation of HCAR2 by niacin: benefits beyond lipid lowering","volume":"20","author":"Tuteja","year":"2019","journal-title":"Pharmacogenomics"},{"key":"B134","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11883-019-0787-5","article-title":"Current role of lipoprotein apheresis","volume":"21","author":"Thompson","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.4390","article-title":"A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels","volume":"23","author":"Khetarpal","year":"2017","journal-title":"Nat Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/10715762.2017.1322205","article-title":"Antioxidant therapy for management of oxidative stress induced hypertension","volume":"51","author":"Ahmad","year":"2017","journal-title":"Free Radic Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.2174\/1389450118666170123145357","article-title":"The antioxidant activities of natural polysaccharides","volume":"18","author":"Huang","year":"2017","journal-title":"Curr Drug Targets"},{"key":"B138","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.phrs.2018.12.022","article-title":"Topiramate protects apoE-deficient mice from kidney damage without affecting plasma lipids","volume":"141","author":"Manzini","year":"2019","journal-title":"Pharmacol Res"},{"key":"B139","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5414\/CNCS109509","article-title":"A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka","volume":"6","author":"Hirashima","year":"2018","journal-title":"Clin Nephrol Case Stud"},{"key":"B140","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s13730-019-00380-w","article-title":"A case of apolipoprotein E toyonaka and homozygous apolipoprotein E2\/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes","volume":"8","author":"Kato","year":"2019","journal-title":"CEN Case Rep"},{"key":"B141","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.kint.2019.10.031","article-title":"Apolipoprotein E\u2013related glomerular disorders","volume":"97","author":"Saito","year":"2020","journal-title":"Kidney Int"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.905007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T02:14:58Z","timestamp":1651803298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.905007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":141,"alternative-id":["10.3389\/fmed.2022.905007"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.905007","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"article-number":"905007"}}